Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E A Emini

Showing results (61-70 of 96) with videos related to

Pageof 10
Sort By:
Nature|January 12, 1995
Viral dynamics in human immunodeficiency virus type 1 infectionX Wei, S K Ghosh, M E Taylor, et al.
Journal of Medicinal Chemistry|January 21, 1994
Design and synthesis of peptidomimetic inhibitors of HIV-1 protease and renin. Evidence for improved transportA B Smith, R Hirschmann, A Pasternak, et al.
Antimicrobial Agents and Chemotherapy|May 1, 1993
A nonnucleoside reverse transcriptase inhibitor active on human immunodeficiency virus type 1 isolates resistant to related inhibitorsM E Goldman, J A O'Brien, T L Ruffing, et al.
Journal of Virology|August 1, 1990
Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzeesE A Emini, P L Nara, W A Schleif, et al.
The New England Journal of Medicine|October 7, 1993
A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working GroupM S Saag, E A Emini, O L Laskin, et al.
Science (New York, N.Y.)|September 6, 1991
Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant: further clarificationsG J LaRosa, K Weinhold, A T Profy, et al.
Virology|October 1, 1988
Antigenic analysis of the Epstein-Barr virus major membrane antigen (gp350/220) expressed in yeast and mammalian cells: implications for the development of a subunit vaccineE A Emini, W A Schleif, M E Armstrong, et al.
Journal of Virology|November 1, 1994
Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52DA J Conley, M K Gorny, J A Kessler, et al.
Journal of Molecular Biology|February 12, 2000
X-ray structure of simian immunodeficiency virus integrase containing the core and C-terminal domain (residues 50-293)--an initial glance of the viral DNA binding platformZ Chen, Y Yan, S Munshi, et al.
Antimicrobial Agents and Chemotherapy|June 1, 1994
Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitorsV W Byrnes, E A Emini, W A Schleif, et al.
Pageof 10

Showing results (61-70 of 96) with videos related to

Sort By:
Pageof 10
Nature|January 12, 1995
Viral dynamics in human immunodeficiency virus type 1 infectionX Wei, S K Ghosh, M E Taylor, et al.
Journal of Medicinal Chemistry|January 21, 1994
Design and synthesis of peptidomimetic inhibitors of HIV-1 protease and renin. Evidence for improved transportA B Smith, R Hirschmann, A Pasternak, et al.
Antimicrobial Agents and Chemotherapy|May 1, 1993
A nonnucleoside reverse transcriptase inhibitor active on human immunodeficiency virus type 1 isolates resistant to related inhibitorsM E Goldman, J A O'Brien, T L Ruffing, et al.
Journal of Virology|August 1, 1990
Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzeesE A Emini, P L Nara, W A Schleif, et al.
The New England Journal of Medicine|October 7, 1993
A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working GroupM S Saag, E A Emini, O L Laskin, et al.
Science (New York, N.Y.)|September 6, 1991
Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant: further clarificationsG J LaRosa, K Weinhold, A T Profy, et al.
Virology|October 1, 1988
Antigenic analysis of the Epstein-Barr virus major membrane antigen (gp350/220) expressed in yeast and mammalian cells: implications for the development of a subunit vaccineE A Emini, W A Schleif, M E Armstrong, et al.
Journal of Virology|November 1, 1994
Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52DA J Conley, M K Gorny, J A Kessler, et al.
Journal of Molecular Biology|February 12, 2000
X-ray structure of simian immunodeficiency virus integrase containing the core and C-terminal domain (residues 50-293)--an initial glance of the viral DNA binding platformZ Chen, Y Yan, S Munshi, et al.
Antimicrobial Agents and Chemotherapy|June 1, 1994
Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitorsV W Byrnes, E A Emini, W A Schleif, et al.
Pageof 10